Pharmaceutical Sciences, Biologics Development and Manufacturing, Seattle Genetics, Bothell, Washington 98021.
Pharmaceutical Sciences, Biologics Development and Manufacturing, Seattle Genetics, Bothell, Washington 98021.
J Pharm Sci. 2020 Jan;109(1):761-768. doi: 10.1016/j.xphs.2019.07.021. Epub 2019 Jul 31.
Closed system transfer devices (CSTD) are a supplemental engineering control designed to reduce occupational exposure of hazardous drugs and are currently implemented in accordance with evolving regulations. Owing to the novelty and complexity of these devices and their importance in clinical in-use testing, here we evaluated FDA-approved CSTD, assessing product quality through stability indicating assays to determine any drug product incompatibilities. Six devices were used in a simulated compounding and administration of a late-phase IgG1 antibody-drug conjugate (ADC) and the resulting samples were analyzed for visible and subvisible particle counts by light obscuration and micro-flow imaging, physical stability by size exclusion chromatography, and biological activities by relative potency. Potential challenges included improper fit of CSTD components, loss of product to void volume, and material incompatibility. Results showed compatibility of the ADC with the 6 CSTD evaluated. One CSTD introduced subvisible particles into the ADC during compounding that were identified through morphological assessment as silicone oil. This study highlights the importance of clinical in use testing with new devices and proposes strategies to mitigate the risk of drug product incompatibility with CSTD.
密闭式转移装置(CSTD)是一种补充工程控制手段,旨在降低危险药物的职业暴露风险,目前正在根据不断发展的法规进行实施。由于这些装置的新颖性和复杂性及其在临床使用测试中的重要性,我们在这里评估了经过 FDA 批准的 CSTD,通过稳定性指示分析来评估产品质量,以确定任何药物产品的不相容性。在模拟的配制和晚期 IgG1 抗体药物偶联物(ADC)的给药过程中使用了六种装置,并通过光漫射和微流成像分析了可见和亚可见颗粒计数、通过尺寸排阻色谱分析了物理稳定性、通过相对效力分析了生物活性。潜在的挑战包括 CSTD 组件配合不当、产品损失到空隙体积以及材料不相容性。结果表明,在评估的 6 种 CSTD 中,ADC 与 CSTD 相容。一种 CSTD 在配制过程中向 ADC 中引入了亚可见颗粒,通过形态评估鉴定为硅油。本研究强调了对新装置进行临床使用测试的重要性,并提出了降低 CSTD 与药物产品不相容性风险的策略。